Physician profile
Eric J Kozlow
NPI 1710943790
$99,718.15
in general payments reported to CMS, 2019-2025
46 companies · $21K in 2025
The $21K reported for 2025 was more than what 92% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,137 · 2020: $5,846 · 2021: $2,414 · 2022: $22K · 2023: $22K · 2024: $18K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Food and Beverage: $13K · Education: $280 · Consulting Fee: $134 · Travel and Lodging: $70.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $47,290.00 |
| Food and Beverage | $13,338.38 |
| Education | $280.28 |
| Consulting Fee | $134.35 |
| Travel and Lodging | $70.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $77,976.69 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Amgen INC. | $7,107.58 | 2021-2025 | Tezspire |
| Glaxosmithkline, LLC. | $2,217.44 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,948.40 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,378.63 | 2019-2025 | |
| Abbvie INC. | $753.94 | 2021-2025 | |
| Csl Behring | $743.80 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Novartis Pharmaceuticals Corporation | $691.38 | 2019-2025 | |
| Grifols USA, LLC | $551.18 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Pfizer INC. | $540.84 | 2019-2025 | |
| Incyte Corporation | $475.76 | 2021-2025 | Opzelura |
| Genentech USA, INC. | $443.67 | 2019-2025 | Xolair |
| Biocryst US Sales Co., LLC | $419.10 | 2021-2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $377.08 | 2020-2025 | Takhzyro, Glassia, Hyqvia |
| Leo Pharma INC. | $350.54 | 2022-2025 | Adbry, Anzupgo |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Kozlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.